

24. Lin C, Itti E, Haioun C, et al. Early ^{18}F -FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. *J Nucl Med.* 2007;48:1626–1632.
25. Song H, Du Y, Sgouros G, Prideaux A, Frey E, Wahl RL. Therapeutic potential of ^{90}Y - and ^{131}I -labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis. *J Nucl Med.* 2007;48:150–157.
26. Juweid M, Sharkey RM, Alavi A, et al. Regression of advanced refractory ovarian cancer treated with iodine-131-labeled anti-CEA monoclonal antibody. *J Nucl Med.* 1997;38:257–260.
27. Hall EJ, Giaccia AJ. Cell survival curves. In: Hall EJ, Giaccia AJ, eds. *Radiobiology for the Radiologist*. Philadelphia, PA: Lippincott Williams & Wilkins; 2006:30–46.
28. Bodet-Milin C, Kraeber-Bodere F, Dupas B, et al. Evaluation of response to fractionated radioimmunotherapy with ^{90}Y -epratuzumab in non-Hodgkin's lymphoma by ^{18}F -fluorodeoxyglucose positron emission tomography. *Haematologica.* 2008;93:390–397.
29. Shrikanthan S, Berkowitz A, Dadparvar S, Schuster S, Alavi A. Radioimmunotherapy in lymphoma and the role of FDG-PET in assessment of response [abstract]. *J Nucl Med.* 2006;47(suppl 1):450P.
30. Aviles A, Neri N, Delgado S, et al. Residual disease after chemotherapy in aggressive malignant lymphoma: the role of radiotherapy. *Med Oncol.* 2005; 22:383–387.
31. Hamstra DA, Gross BH, Francis R, Estes J, Wahl RL, Kaminski MS. Does the pattern of failure impact the use of single-agent ^{131}I -tositumomab for follicular lymphoma? [abstract]. *Int J Radiation Oncology.* 2006;66(3 suppl):S506.

Errata

In the article “Comparison Between Adenoviral and Retroviral Vectors for the Transduction of the Thymidine Kinase PET Reporter Gene in Rat Mesenchymal Stem Cells,” by Roelants et al. (*J Nucl Med.* 2008;49:1836–1844), the abstract incorrectly states that mesenchymal stem cells either were incubated in advance with 9-(4- ^{18}F -fluoro-3-[hydroxymethyl]butyl)guanine (^{18}F -FHBG) or were administered after an intravenous injection of ^{18}F -FHBG. In fact, either the cells were incubated in advance with ^{18}F -FHBG, or they were administered and ^{18}F -FHBG was thereafter intravenously administered. The authors regret the error.

In the article “Reproducibility of Standardized Uptake Value Measurements Determined by ^{18}F -FDG PET in Malignant Tumors,” by Nahmias and Wahl (*J Nucl Med.* 2008;49:1804–1808), 2 acknowledgments were omitted. The study was supported in part by grant R33 CA94317 from the National Institutes of Health, and research technologist Misty Long acquired all study data. The authors regret the omissions.